Dennis Weibling Joins Board of Directors

Effective September 4, 2015, Dennis Weibling has joined the Lazure Scientific, Inc. Board of Directors. Mr. Weibling is currently the managing director of Rally Capital LLC, a venture capital firm based in Kirkland, Washington. He has served on the board of more than 10 companies, including Sotheby’s board as chairman of the audit and finance committees, a position he’s held since 2006. Mr. Weibling was president of Eagle River, Inc. from 1993 to 2001, and as vice chairman of Eagle River Investments from 2002 to 2004. He served as CEO of Nextel Communications Inc. from 1995 to 1996 and as a Director of Nextel from 1995 until 2004. At Nextel, he was a member and chairman of the operations, audit, finance, and compensation committees at various times during that period. Mr. Weibling served as a board member of Nextel Partners from 1998 to 2006 and chaired the audit committee. He also served on the board of public company XO Communications, Inc. from 1996 to 2003 on the compensation and audit committee. He served as a Trustee for Seattle Pacific University from 2002 to 2013 and as Chair his last four years. He earned his CPA credential and was a partner at Clark Nuber & Co in Bellevue, Washington from 1986 to 1993. Mr. Weibling received his bachelor’s degree from Wittenberg University in Springfield, Ohio and his Juris Doctor and master’s degrees from the University of Nebraska.

 

“Mr. Weibling adds additional business acumen and transactional expertise to an already strong Board of Directors,” remarked CEO, Charles Hill.  “I am pleased to have Mr. Weibling join us as we enter this next important and critical phase.”

Human Trials Expand to Pretoria, South Africa

Issaquah, WA Lazure Scientific, Inc. announced today the expansion of their prostate cancer clinical trial to Pretoria, South Africa. The first human in the expansion was treated using the Lazure Low Dose Alternating Current (LDAC) prostate cancer treatment device on February 13, 2014 at The Urology Hospital in Pretoria as part of Lazure’s Study of…

LaZure Treats First Human Patient

Issaquah, WA LaZure Scientific, Inc. announced today that the first human patient was treated using LaZure’s Low Dose Alternating Current (LDAC) prostate cancer treatment device on Friday September 14, 2012.  The treatment was performed at the Medulla Clinic in the Republic of Georgia as part of LaZure’s first-in-man Study of Feasibility of Low-Dose Alternating Electric Current (LDAC)…

AUA Show a Success for LaZure

LaZure Scientific, Inc. was a first time exhibitor at the American Urological Association (AUA) Conference and Exhibition held at the Atlanta World Congress Center from May 19 -23, 2012.  The AUA show — attended by over 10,000 urologists from around the globe — represented the first show for LaZure and it’s proprietary LDAC Technology.  The feedback from urologists…

Successful Completion of $3.3 M Series C Equity First Close

LaZure Scientific recently announced the successful first closing of $3.3M for its Series C Preferred Stock offering. The Company plans to raise an additional $1.7M to complete the $5M Series C round. The funds will be used to complete LaZure’s “first-in-man” clinical trial of the LDAC prostate cancer treatment device and to continue device and…

Completion of Successful Series B Equity Financing

LaZure Scientific recently announced the successful close of its Series B preferred Equity Financing. Total proceeds from the round were not disclosed, however, LaZure CEO Charles Hill noted “Funds from our Successful Series B Round will allow us to continue our preclinical testing to validate the safety and effectiveness of our technology and continue making…

Announcing Publication of Peer Reviewed Paper

LaZure Scientific, Inc. recently announced that results from its human prostate cancer xenograft study have been accepted for publication in the December 2009 issue of the medical journal The Prostate. “We are pleased that the editors and reviewers at The Prostate feel our study results our worthy of publication,” remarked Charles Hill, CEO of LaZure…

Human Prostate Cancer Xenograft Study Complete

LaZure Scientific, Inc. recently announced the completion of a non-clinical study to evaluate the effect of its proprietary Low Dose Alternating Electric Current (LDAEC) therapy on human prostate cancer xenografts in immune deficient mice. The study included over ninety mice implanted with human prostate cancer tumors that received treatment with the LDAEC technology. Results from…